Completely agree AD.
20-30 Million, to complete one registration trial, with a drug that is looking like it has a real chance. Once approved and on the market, possibly in 2026, 20-30 million will equate to a fortnights gross revenue with patent protection out to 2038.
I'm happy to sit back and let the CEO supported by the Chairman and and newest director both of whom have many contacts and runs on the board, find the required funds.
At this stage things are looking good.
Cheers
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1122
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 18.5¢ | $2.617M | 12.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 231369 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
19.0¢ |
Change
0.000 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 23.5¢ | 24.0¢ | 18.5¢ | 9241539 | ||
| Last updated 16.02pm 17/05/2024 ? | |||||
| PAA (ASX) Chart |